Treatment of Hepatitis c by Using Direct-acting Antiviral
- Conditions
- Hepatitis C
- Interventions
- Drug: Direct Acting Antivirals
- Registration Number
- NCT05372874
- Lead Sponsor
- Tanta University
- Brief Summary
Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to disease progression. Chronic stress shunt tryptophan which is essential amino acid toward kynurenic pathway leading to lower level of serotonin and melatonin level. Currently, direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- chronic hepatitis C patients had no other cause of liver disease
Read More
Exclusion Criteria
- Patients with hepatitis B virus (HBV).
- Patients with acute hepatitis.
- Patients with renal insufficiency.
- Patients with Hepatocellular carcinoma (HCC) or other types of malignancy.
- Patients on current use of melatonin.
- Patients using of any of medications that have interaction with melatonin.
- Patients work in night shifts.
- Patients are consuming a lot of caffeine or heavy smokers.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description sofosbuvir/daclatasvir treated group (group 2) Direct Acting Antivirals - sofosbuvir /daclatasvir/ ribavirin treated group (group 3) Direct Acting Antivirals -
- Primary Outcome Measures
Name Time Method Change in malondialdehyde (MDA) level. 12 weeks following end of treatment. Malondialdehyde (MDA) levels will be measured by the TBARS assay (thiobarbituric acid reactive substance assay)
Change in melatonin level. 12 weeks following end of treatment. Melatonin will be measured by using immunological method.
- Secondary Outcome Measures
Name Time Method